ERBB2 and breast cancer: Patients with hormone receptor (HR)–positive and human epidermal growth factor receptor 2 (ERBB2, formerly HER2)–negative breast cancer had a higher risk for overall death in the CBC group (hazard ratio, 1.882; 95% CI, 1.143-3.098) compared with the no-CBC group.